CNO Financial Group entered into a Sixth Amended and Restated Section 382 Rights Agreement to extend its existing 'poison pill' through November 13, 2029. The agreement is designed to protect the company's tax net operating loss carryforwards by deterring any person from acquiring 4.99% or more of the company's outstanding common stock without board approval.
CNO Financial Group reported Q3 2026 net operating income of $179.1 million, or $1.90 per diluted share, representing a 47% increase in operating EPS year-over-year. The company raised its full-year 2026 operating EPS guidance midpoint by 9% following its 17th consecutive quarter of sales growth and a successful reinsurance transaction with its Bermuda affiliate.
Term
Q3 2026
“CNO delivered an excellent quarter, with operating earnings per share up 47% and our 17th consecutive quarter of sales growth. Our momentum reflects disciplined execution across the business and continued improvement in profitability.”
Gary C. Bhojwani, chief executive officer
“Based on these results, we are raising our full-year operating earnings per share guidance. We also executed our 3rd reinsurance transaction with our Bermuda affiliate, supporting our focus on serving middle-income households.”